190 related articles for article (PubMed ID: 15656327)
1. Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.
Bajetta E; Vercammen E; Reinhardt U; Janmohamed R; da Costa RM; Matulonis U; Guastalla JP;
Tumori; 2004; 90(5):449-57. PubMed ID: 15656327
[TBL] [Abstract][Full Text] [Related]
2. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
[TBL] [Abstract][Full Text] [Related]
3. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
4. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
Hudis CA; Vogel CL; Gralow JR; Williams D;
Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
[TBL] [Abstract][Full Text] [Related]
6. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.
Glaspy J; Degos L; Dicato M; Demetri GD
Oncologist; 2002; 7(2):126-35. PubMed ID: 11961196
[TBL] [Abstract][Full Text] [Related]
7. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
Chang J; Couture F; Young S; McWatters KL; Lau CY
J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
[TBL] [Abstract][Full Text] [Related]
8. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
Crouch Z; DeSantis ER
Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
[TBL] [Abstract][Full Text] [Related]
9. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
10. Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial.
Pronzato P; Cortesi E; van der Rijt CC; Bols A; Moreno-Nogueira JA; de Oliveira CF; Barrett-Lee P; Ostler PJ; Rosso R;
Oncologist; 2010; 15(9):935-43. PubMed ID: 20798194
[TBL] [Abstract][Full Text] [Related]
11. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.
Campos SM; Duh MS; Lefebvre P; Rosberg J
J Natl Compr Canc Netw; 2005 Nov; 3(6):807-16. PubMed ID: 16316616
[TBL] [Abstract][Full Text] [Related]
12. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
[TBL] [Abstract][Full Text] [Related]
13. A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy.
Pawlicki M; Jassem J; Bösze P; Lotan C; Kurteva GP; Siddiqui M; Kosmidis PA; Rigatos GA; Kansu E; Durkovic P; Aziz Z; Al Idrissi H; Roth A; Cozma G
Anticancer Drugs; 1997 Nov; 8(10):949-57. PubMed ID: 9436638
[TBL] [Abstract][Full Text] [Related]
14. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
Glaspy J; Bukowski R; Steinberg D; Taylor C; Tchekmedyian S; Vadhan-Raj S
J Clin Oncol; 1997 Mar; 15(3):1218-34. PubMed ID: 9060566
[TBL] [Abstract][Full Text] [Related]
15. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
Ariganello O; Mancuso A; Di Molfetta M; Diana F; Beccaglia P; Cortesi E; De Marinis F
Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
[TBL] [Abstract][Full Text] [Related]
17. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L
Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
[TBL] [Abstract][Full Text] [Related]
19. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
Afdhal NH; Dieterich DT; Pockros PJ; Schiff ER; Shiffman ML; Sulkowski MS; Wright T; Younossi Z; Goon BL; Tang KL; Bowers PJ;
Gastroenterology; 2004 May; 126(5):1302-11. PubMed ID: 15131791
[TBL] [Abstract][Full Text] [Related]
20. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.
Moebus V; Jackisch C; Schneeweiss A; Huober J; Lueck HJ; du Bois A; Thomssen C; Kurbacher C; Kuhn W; Nitz U; Runnebaum IB; Hinke A; Kreienberg R; Untch M;
J Natl Cancer Inst; 2013 Jul; 105(14):1018-26. PubMed ID: 23860204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
